Cancer screening rates lower among those with fatalistic attitudes

September 27, 2011

Even if health care is free, colorectal cancer screening rates among those without financial means are still low, and results of a new study suggest that may be due to an idea psychologists call cancer fatalism.

Anne Miles, Ph.D., a lecturer in psychology at Birkbeck, University of London, said those who felt that the cancer screenings wouldn't help, or they were going to die of cancer anyway, often failed to comply with screening recommendations.

Her findings are published in a recent issue of , Biomarkers & Prevention, a journal of the American Association for Cancer Research.

"In England, the screenings are free and the subsequent health treatments are free as well, yet people of lower socioeconomic status still do not get screened. We wanted to find out what else was going on," she said.

Miles and her colleagues analyzed data from 529 adults aged 60 to 69 who had completed a series of surveys measuring their socioeconomic status, self-rated health and rate of cancer fatalism. These measures were tested against the rate of fecal occult blood testing.

They found that men and women with higher socioeconomic status, better self-rated health and lower cancer fatalism were 56 percent more likely to undergo by fecal occult blood testing.

Miles said cancer can be reduced if properly identified.

"There is clearly something else going on here besides costs. We need to understand peoples' attitudes toward screening," said Miles. "If they think it won't help, they won't do it, even if it's free."

Explore further: Colorectal cancer screening rates on rise among Medicare beneficiaries due to expansion of coverage

Related Stories

Colorectal cancer screening rates on rise among Medicare beneficiaries due to expansion of coverage

May 3, 2011
Colorectal cancer screening rates increased for Medicare beneficiaries when coverage was expanded to average-risk individuals, but racial disparities still exist, according to researchers at The University of Texas Health ...

Recommended for you

New therapeutic approach for difficult-to-treat subtype of ovarian cancer identified

July 24, 2017
A potential new therapeutic strategy for a difficult-to-treat form of ovarian cancer has been discovered by Wistar scientists. The findings were published online in Nature Cell Biology.

Anti-cancer chemotherapeutic agent inhibits glioblastoma growth and radiation resistance

July 24, 2017
Glioblastoma is a primary brain tumor with dismal survival rates, even after treatment with surgery, chemotherapy and radiation. A small subpopulation of tumor cells—glioma stem cells—is responsible for glioblastoma's ...

Immune cells the missing ingredient in new bladder cancer treatment

July 24, 2017
New research offers a possible explanation for why a new type of cancer treatment hasn't been working as expected against bladder cancer.

No dye: Cancer patients' gray hair darkened on immune drugs

July 21, 2017
Cancer patients' gray hair unexpectedly turned youthfully dark while taking novel drugs, and it has doctors scratching their heads.

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.